A new AIDS vaccine heads to clinical trials

One silver lining to the covid-19 pandemic has been the speed with which effective vaccines have been developed. Victims of other pandemics have not been so lucky. Three decades of attempts to create a vaccine against hiv, the virus that causes aids, have proved fruitless. The latest setback came on August 31st, when an experimental vaccine produced by Johnson & Johnson, an American pharmaceutical firm, flunked a clinical trial. One obstacle is hiv’s genetic slipperiness. The virus has a high mutation rate, which helps it adapt to evade both natural immune systems and artificial vaccines.
Read more: https://www.economist.com/science-and-technology/a-new-aids-vaccine-heads-to-clinical-trials/21804378?source=Snapzu